A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC)

Trial Profile

A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs XL 999 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Exelixis
  • Most Recent Events

    • 16 Feb 2010 Planned end date (1 May 2008) added as reported by ClinicalTrials.gov.
    • 23 Apr 2008 Status changed from suspended to discontinued, reported by ClinicalTrials.gov. The trial was discontinued due to safety concerns.
    • 09 Jan 2008 Status changed from recruiting to suspended according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top